SecBot SecBot
SECBOTREPLAY Home › Report › BMY

BMY · Bristol-Myers Squibb Co filed a definitive proxy statement (DEFA14A)…

BRISTOL MYERS SQUIBB CO · DEFA14A filed Mar 25, 2026 at 16:35 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Mar 25, 2026 at 16:35 ET

Bristol-Myers Squibb Co filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting. The filing outlines proposals for shareholder vote, including the election of 11 directors, an advisory vote on executive compensation, approval of a new stock award plan, ratification of the auditor, and a shareholder proposal to make the board chair independent.

  • Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting
  • Proposals include election of 11 director nominees
  • Advisory vote on executive compensation
  • Vote to approve the 2026 Stock Award and Incentive Plan

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access